Arbutus Biopharma Corp (ABUS)vsRevolution Medicines Inc (RVMD)
ABUS
Arbutus Biopharma Corp
$4.25
-2.30%
HEALTHCARE · Cap: $884.97M
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Arbutus Biopharma Corp generates 25701% more annual revenue ($191.44M vs $742,000). ABUS leads profitability with a 84.0% profit margin vs 0.0%. ABUS earns a higher WallStSmart Score of 63/100 (C+).
ABUS
Buy63
out of 100
Grade: C+
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 62 in profit
Keeps 84 of every $100 in revenue as profit
Strong operational efficiency at 94.4%
Revenue surging 10055.0% year-over-year
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Distress zone — elevated risk
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABUS
The strongest argument for ABUS centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 84.0% and operating margin at 94.4%. Revenue growth of 10055.0% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : ABUS
The primary concerns for ABUS are EPS Growth, Market Cap, Free Cash Flow.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
ABUS profiles as a growth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
ABUS is growing revenue faster at 10055.0% — sustainability is the question.
ABUS generates stronger free cash flow (-8M), providing more financial flexibility.
Bottom Line
ABUS scores higher overall (63/100 vs 24/100), backed by strong 84.0% margins and 10055.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arbutus Biopharma Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?